4basebio Plc - Director's Dealing
November 29 2024 - 7:30AM
UK Regulatory
4basebio Plc - Director's Dealing
PR Newswire
LONDON, United Kingdom, November 29
29
November 2024
4basebio
plc
(“4basebio” or the
"Company")
Director’s
Dealing
29
November 2024 – 4basebio PLC (AIM: 4BB)
(“4basebio” or the “Company”), which develops and commercialises
the large-scale manufacture of synthetic DNA as well as
nanoparticle delivery solutions, announces
that
it was informed by
Dr. Heikki Lanckriet, CEO of the Company, that
he acquired ordinary shares in the Company through the market as
follows:
|
Name |
Number of Shares
Acquired |
Price per Share
(p) |
Shareholding Following
Acquisition |
Shareholding as a
Percentage of Issued Share
Capital |
|
Heikki
Lanckriet |
12,000 |
1,315p |
1,115,288 |
7.27% |
The issued share capital
of the Company comprises 15,477,395 ordinary
shares.
This announcement contains inside information for the
purposes of Article 7 of EU Regulation 596/2014 as amended by
regulation 11 of the market abuse (amendment) (EU Exit) regulations
2019/310.
Enquiries
|
4basebio
PLC
Dr. Heikki
Lanckriet
|
+44 (0)1223 967
943
|
|
Nominated
Adviser
Cairn Financial
Advisers LLP
Jo Turner / Sandy Jamieson
/ Ed Downes
|
+44 (0)20 7213
0880
|
|
Joint Corporate
Broker
RBC Capital
Markets
Rupert Walford / Kathryn
Deegan
|
+44 (0)20 7653
4000
|
|
Joint Corporate
Broker
Cavendish Capital
Markets Limited
Geoff Nash / Nigel
Birks
|
+44 (0)20 7220
0500
|
Notes to
Editors
About
4basebio
4basebio (AIM: 4BB) is an
innovation driven life biotechnology company focused on
accelerating the development of advanced therapy medicinal products
(ATMPs) through its high-performance synthetic DNA products and
non-viral, cell targeting nucleic acid delivery platform. The
Company’s objective is to become a market leader in the manufacture
and supply of high-quality synthetic DNA products for research,
therapeutic and pharmacological use as well as development of
target specific non-viral vectors for the efficient delivery of
payloads in patients.
|
Notification of a Transaction pursuant to Article
19(1) of Regulation (EU) No.
596/2014 |
|
1 |
Details of the person discharging managerial
responsibilities/person closely
associated |
|
a. |
Name |
Dr. Heikki
Lanckriet |
|
2 |
Reason for
notification |
|
|
a. |
Position/Status |
CEO |
|
b. |
Initial
notification/Amendment |
Initial
Notification |
|
3 |
Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor |
|
a. |
Name |
4basebio
plc |
|
b. |
LEI |
213800E2DX9EAIUNCB30 |
|
4 |
Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have been
conducted |
|
a. |
Description of the financial instrument, type of
instrument
Identification Code |
Ordinary
Shares
ISIN:
GB00BMCLYF79 |
|
b. |
Nature of the
transaction |
Acquisition of ordinary
shares |
|
|
|
|
Price(s) per share
(p) |
Volume(s) |
|
|
1,315p |
12,000 |
|
|
|
|
d. |
Aggregated
information
|
-
12,000
-
1,315 pence per
share
|
|
e. |
Date of the
transaction |
28/11/2024 |
|
f. |
Place of the
transaction |
London Stock Exchange,
AIM |
4basebio (LSE:4BB)
Historical Stock Chart
From Dec 2024 to Jan 2025
4basebio (LSE:4BB)
Historical Stock Chart
From Jan 2024 to Jan 2025
